
{::comment}
Cardiology
{:/comment}

{::comment}
ACS
{:/comment}

[^amsterdam2014]: Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017

[^ogara2013]: O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2013;61(4):e78-e140. doi:[10.1016/j.jacc.2012.11.019](https://doi.org/10.1016/j.jacc.2012.11.019)

[^driver2017]: Driver BE, Khalil A, Henry T, Kazmi F, Adil A, Smith SW. A new 4-variable formula to differentiate normal variant ST segment elevation in V2-V4 (early repolarization) from subtle left anterior descending coronary occlusion - Adding QRS amplitude of V2 improves the model. *Journal of Electrocardiology*. 2017;50(5):561-569. doi:[10.1016/j.jelectrocard.2017.04.005](https://doi.org/10.1016/j.jelectrocard.2017.04.005)

[^levine2016]: Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. *Journal of the American College of Cardiology*. 2016;68(10):1082-1115. doi:[10.1016/j.jacc.2016.03.513](https://doi.org/10.1016/j.jacc.2016.03.513)

[^smith2012]: Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. *Annals of Emergency Medicine*. 2012;60(6):766-776. doi:[10.1016/j.annemergmed.2012.07.119](https://doi.org/10.1016/j.annemergmed.2012.07.119)

[^thygesen]: Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third Universal Definition of Myocardial Infarction. :16.

[^levine2015]: Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2016;67(10):1235-1250. doi:[10.1016/j.jacc.2015.10.005](https://doi.org/10.1016/j.jacc.2015.10.005)

{::comment}
HTN
{:/comment}

[^whelton2018]: Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Journal of the American College of Cardiology*. 2018;71(19):e127-e248. doi:[10.1016/j.jacc.2017.11.006](https://doi.org/10.1016/j.jacc.2017.11.006)

[^benken2018]: Benken ST. ACCP Hypertensive Emergencies. 2018. Available at: https://www.accp.com/docs/bookstore/ccsap/ccsap2018b1_sample.pdf

{::comment}
VTE
{:/comment}

[^kearon2016]: Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2):315-352. doi:[10.1016/j.chest.2015.11.026](https://doi.org/10.1016/j.chest.2015.11.026)

[^gould2012]: Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients. Chest. 2012;141(2):e227S-e277S. doi:[10.1378/chest.11-2297](https://doi.org/10.1378/chest.11-2297)

{::comment}
CHF
{:/comment}

[^yancy2013]: Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;128(16). doi:[10.1161/CIR.0b013e31829e8776](https://doi.org/10.1161/CIR.0b013e31829e8776)

[^yancy2017]: Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Journal of the American College of Cardiology*. 2017;70(6):776-803. doi:[10.1016/j.jacc.2017.04.025

{::comment}
HLD
{:/comment}

[^grundy2018]: Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *Journal of the American College of Cardiology*. November 2018. doi:[10.1016/j.jacc.2018.11.003](https://doi.org/10.1016/j.jacc.2018.11.003)

[^jacobson2015]: Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. *Journal of Clinical Lipidology*. 2015;9(2):129-169. doi:[10.1016/j.jacl.2015.02.003](https://doi.org/10.1016/j.jacl.2015.02.003)

[^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838)

{::comment}
Critical Care
{:/comment}

{::comment}
Hypotension Management
{:/comment}

[^weingart2015]: Weingart S. Push-dose pressors for immediate blood pressure control. *Clinical and Experimental Emergency Medicine*. 2015;2(2):131-132. doi:[10.15441/ceem.15.010](https://doi.org/10.15441/ceem.15.010)

[^hollenberg2011]: Hollenberg SM. Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847-855. doi:[10.1164/rccm.201006-0972CI](https://doi.org/10.1164/rccm.201006-0972CI)

[^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838)

[^overgaard2008]: Overgaard CB, Džavík V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-1056. doi:[10.1161/CIRCULATIONAHA.107.728840](https://doi.org/10.1161/CIRCULATIONAHA.107.728840)

{::comment}
Stress Ulcer Prophylaxis
{:/comment}

[^barletta2016]: Barletta JF, Bruno JJ, Buckley MS, Cook DJ. Stress Ulcer Prophylaxis: *Critical Care Medicine*. 2016;44(7):1395-1405. doi:[10.1097/CCM.0000000000001872](https://doi.org/10.1097/CCM.0000000000001872)

[^erstad1999]: Erstad BL, et al. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. 1999.


{::comment}
ID
{:/comment}

{::comment}
Vancomycin Dosing
{:/comment}

[^deryke2009]: Deryke CA, Alexander DP. Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration. *Hospital Pharmacy*. 2009;44(9):751-765. doi:[10.1310/hpj4409-751](https://doi.org/10.1310/hpj4409-751)

[^matzkel1984]: Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. *Antimicrobial Agents and Chemotherapy*. 1984;25(4):433-437. doi:[10.1128/AAC.25.4.433](https://doi.org/10.1128/AAC.25.4.433)

[^rybak2009]: Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy*. 2009;66(1):82-98. doi:[10.2146/ajhp080434](https://doi.org/10.2146/ajhp080434)

{::comment}
Aminoglycoside Dosing
{:/comment}

[^mui2017]: Mui, E. Stanford Health Care Aminoglycoside Dosing Guideline. 2017. [Link](http://med.stanford.edu/bugsanddrugs/dosing-protocols/_jcr_content/main/panel_builder/panel_0/download_2/file.res/Aminoglycoside%20Dosing%20Guide%202017-08-23.pdf)

[^nicolau1995]: Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. *Antimicrobial Agents and Chemotherapy*. 1995;39(3):650-655. doi:[10.1128/AAC.39.3.650](https://doi.org/10.1128/AAC.39.3.650)

{::comment}
Pulmononolgy
{:/comment}

[^goldCOPD]: Vogelmeier C, Agusti A, *et al*. Global Initiative for Chronic Obstructive Lung Disease. [Available Here](https://goldcopd.org/wp-content/uploads/2018/02/WMS-GOLD-2018-Feb-Final-to-print-v2.pdf)


{::comment}
Endocrinology
{:/comment}

[^adaDM2018]: Professional Practice Committee: *Standards of Medical Care in Diabetes—2018*. *Diabetes Care*. 2018;41:S3-S3. doi:[10.2337/dc18-Sppc01](https://doi.org/10.2337/dc18-Sppc01)
[^acceDM2018]: Garber AJ, Abrahamson MJ, Barzilay JI, et al. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – *2018 EXECUTIVE SUMMARY*. *Endocrine Practice*. 2018;24(1):91-120. doi:[10.4158/CS-2017-0153](https://doi.org/10.4158/CS-2017-0153)

[^adaHGC2004]: Hyperglycemic Crises in Diabetes. *Diabetes Care*. 2004;27(Supplement 1):S94-S102. doi:[10.2337/diacare.27.2007.S94](https://doi.org/10.2337/diacare.27.2007.S94)


{::comment}
Textbooks
{:/comment}

{::comment}
Pharmacology
{:/comment}

[^dipiro]: DiPiro JT, ed. *Pharmacotherapy: A Pathophysiologic Approach*. Tenth edition. New York: McGraw-Hill Education; 2017.

{::comment}
Emergency Medicine
{:/comment}

[^tintinalli]: Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. *Tintinalli’s Emergency Medicine: A Comprehensive Study Guide*. Eight edition. New York: McGraw-Hill Education; 2016.

{::comment}
Websites
{:/comment}

{::comment}
Drug Resources
{:/comment}

[^lexi]: Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com).
